MILAN—Prostate cancer (PCa) patients with a tumor visible on baseline magnetic resonance imaging (MRI) scans are more likely to experience radiologic progression while on active surveillance than those without a visible lesion, researchers reported at the 28th annual congress of the European Association of Urology.

Ashley Ridout, BM BCh, of University College London, and colleagues reviewed data from men on active surveillance for histologically-proven PCa who had undergone repeat multiparametric MRI. The study population included 196 men: 137 with low-risk and 59 with intermediate-risk PCa. The mean PSA at presentation was 6.91 ng/mL. The cumulative follow-up time was 524.58 patient-years.

Of the 196 patients, 78 (39.8%) had a visible lesion on baseline MRI and 118 (60.2%) did not. Of the patients with a visible lesion, 37 (47.4%) demonstrated radiologic progression compared with only 21 (17.8%) of those without a visible lesion, which translated into a 2.6 times increased likelihood of radiologic progression associated with the presence of a visible lesion on initial MRI.

Continue Reading

“We conclude from this [study] that individuals without a visible lesion at baseline are less likely to show radiological progression,” Dr. Ridout told colleagues.